PolyPid to Host Conference Call and Webcast to Discuss D-PLEX₁₀₀ SHIELD II Phase 3 Trial Topline Results on Monday, June 9, 2025

Group 1 - PolyPid Ltd. is a late-stage biopharma company focused on improving surgical outcomes through innovative therapeutics [4] - The company will host a conference call on June 9, 2025, to report topline data from the SHIELD II Phase 3 trial for D-PLEX100, aimed at preventing surgical site infections in abdominal colorectal surgery [1][2] - D-PLEX100 is currently in Phase 3 clinical trials, while PolyPid is also testing OncoPLEX for solid tumors, starting with glioblastoma [4] Group 2 - The conference call is scheduled for 8:30 AM Eastern Time, and participants are encouraged to register at least 5 minutes prior to the call [2][3] - PolyPid's proprietary PLEX technology allows for controlled, prolonged-release of drugs, enhancing the delivery of Active Pharmaceutical Ingredients [4]